Korro Bio, Inc.

KRRO ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2018 FY2017
Revenue
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $11.9M $12.0M
SG&A Expense $7.1M $4.3M
Operating Income $-18.9M $-16.3M
Operating Margin
Interest Expense
Pretax Income
Income Tax Expense
Net Income $-19.2M $-20.2M
Net Margin
EPS (Basic) $-0.35 $-0.80
EPS (Diluted) $-0.35 $-0.80
Shares Outstanding (Basic) 75.0M
Shares Outstanding (Diluted) 75.0M
Dividends Per Share
← Newer Page 2 of 2 Older →